Shirin Bruderer

754 total citations
26 papers, 620 citations indexed

About

Shirin Bruderer is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Shirin Bruderer has authored 26 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Cardiology and Cardiovascular Medicine and 7 papers in Molecular Biology. Recurrent topics in Shirin Bruderer's work include Pulmonary Hypertension Research and Treatments (12 papers), Nitric Oxide and Endothelin Effects (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Shirin Bruderer is often cited by papers focused on Pulmonary Hypertension Research and Treatments (12 papers), Nitric Oxide and Endothelin Effects (6 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Shirin Bruderer collaborates with scholars based in Switzerland, France and Germany. Shirin Bruderer's co-authors include Jasper Dingemanse, Patricia N. Sidharta, Priska Kaufmann, Alexander Treiber, Tim Mant, Päivi Äänismaa, Gérard Hopfgartner, Michael Seiberling, Daniela Baldoni and Joanne Marjason and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Plant Molecular Biology and British Journal of Clinical Pharmacology.

In The Last Decade

Shirin Bruderer

26 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shirin Bruderer Switzerland 15 328 288 182 105 88 26 620
Man-Ling Liu China 11 129 0.4× 49 0.2× 176 1.0× 44 0.4× 24 0.3× 14 435
Lucía Baila-Rueda Spain 15 27 0.1× 92 0.3× 179 1.0× 95 0.9× 14 0.2× 35 616
Sabine Pestel Germany 10 125 0.4× 24 0.1× 142 0.8× 145 1.4× 7 0.1× 20 451
Karin Simon Brazil 13 63 0.2× 53 0.2× 146 0.8× 77 0.7× 15 0.2× 27 455
B Brennan United Kingdom 10 74 0.2× 40 0.1× 108 0.6× 138 1.3× 10 0.1× 14 573
Alicja Pakiet Poland 11 38 0.1× 41 0.1× 377 2.1× 90 0.9× 7 0.1× 23 641
Lanfeng Wang China 15 23 0.1× 112 0.4× 385 2.1× 42 0.4× 27 0.3× 25 778
Tarek A. Abd El-Aziz Egypt 13 30 0.1× 191 0.7× 79 0.4× 39 0.4× 46 0.5× 28 459
Yukiko Yoda Japan 10 142 0.4× 32 0.1× 88 0.5× 36 0.3× 8 0.1× 25 521
You Li China 12 77 0.2× 20 0.1× 235 1.3× 27 0.3× 15 0.2× 27 669

Countries citing papers authored by Shirin Bruderer

Since Specialization
Citations

This map shows the geographic impact of Shirin Bruderer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shirin Bruderer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shirin Bruderer more than expected).

Fields of papers citing papers by Shirin Bruderer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shirin Bruderer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shirin Bruderer. The network helps show where Shirin Bruderer may publish in the future.

Co-authorship network of co-authors of Shirin Bruderer

This figure shows the co-authorship network connecting the top 25 collaborators of Shirin Bruderer. A scholar is included among the top collaborators of Shirin Bruderer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shirin Bruderer. Shirin Bruderer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Axelsen, Lene Nygaard, Italo Poggesi, Freya Rasschaert, Juan José Pérez Ruixo, & Shirin Bruderer. (2020). Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects. British Journal of Clinical Pharmacology. 87(1). 119–128. 11 indexed citations
2.
Csonka, Dénes, et al.. (2019). Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects. Clinical Drug Investigation. 39(12). 1223–1232. 4 indexed citations
3.
Bruderer, Shirin, et al.. (2017). Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension. Expert Opinion on Drug Safety. 16(6). 743–751. 7 indexed citations
4.
Juif, Pierre‐Éric, et al.. (2017). A pharmacokinetic drug–drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects. European Journal of Clinical Pharmacology. 73(9). 1121–1128. 16 indexed citations
5.
Bruderer, Shirin, et al.. (2016). Investigation of Potential Pharmacodynamic and Pharmacokinetic Interactions Between Selexipag and Warfarin in Healthy Male Subjects. Clinical Therapeutics. 38(5). 1228–1236.e1. 20 indexed citations
6.
Kaufmann, Priska, et al.. (2015). Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag. American Journal of Cardiovascular Drugs. 15(3). 195–203. 48 indexed citations
7.
Kaufmann, Priska, et al.. (2015). Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. British Journal of Clinical Pharmacology. 80(4). 670–677. 29 indexed citations
8.
Baldoni, Daniela, et al.. (2015). Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration study. International Journal of Clinical Pharmacology and Therapeutics. 53(9). 788–798. 16 indexed citations
9.
Zisowsky, Jochen, Eliane Fuseau, Shirin Bruderer, Andreas Krause, & Jasper Dingemanse. (2014). Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage. European Journal of Clinical Pharmacology. 70(4). 409–419. 5 indexed citations
10.
11.
Hoch, Matthias, Börje Darpö, R Stoltz, et al.. (2014). A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist. Drug Design Development and Therapy. 9. 175–175. 18 indexed citations
12.
Baldoni, Daniela, Shirin Bruderer, Andreas Krause, et al.. (2014). A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial. Clinical Drug Investigation. 34(11). 807–818. 34 indexed citations
13.
Bruderer, Shirin, Joanne Marjason, Patricia N. Sidharta, & Jasper Dingemanse. (2013). Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex. Pharmacology. 91(5-6). 331–338. 31 indexed citations
14.
Fischer, Nadine, et al.. (2013). PP194—Pharmacokinetics of Selexipag in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects. Clinical Therapeutics. 35(8). e77–e78. 1 indexed citations
15.
Bruderer, Shirin, Gérard Hopfgartner, Michael Seiberling, et al.. (2012). Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 42(9). 901–910. 68 indexed citations
16.
Bruderer, Shirin, Päivi Äänismaa, Stéphanie Häusler, et al.. (2011). Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist. The AAPS Journal. 14(1). 68–78. 58 indexed citations
17.
Bruderer, Shirin, et al.. (2010). Influence of Severe Renal Impairment on the Pharmacokinetics of Clazosentan. The Journal of Clinical Pharmacology. 51(3). 413–421. 7 indexed citations
18.
Bruderer, Shirin, et al.. (2010). Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan. British Journal of Clinical Pharmacology. 71(1). 52–60. 7 indexed citations
19.
Kummer, Oliver, Manuel Haschke, Felix Hammann, et al.. (2009). Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan. European Journal of Pharmaceutical Sciences. 38(4). 384–388. 37 indexed citations
20.
Hernández, Marta, Malcolm Burns, Shirin Bruderer, et al.. (2006). A Microarray-based Detection System for Genetically Modified (GM) Food Ingredients. Plant Molecular Biology. 61(1-2). 123–139. 93 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Man-Ling Liu Breakdown of academic impact, for papers by Lucía Baila-Rueda Breakdown of academic impact, for papers by Sabine Pestel Breakdown of academic impact, for papers by Karin Simon Breakdown of academic impact, for papers by B Brennan Breakdown of academic impact, for papers by Alicja Pakiet Breakdown of academic impact, for papers by Lanfeng Wang Breakdown of academic impact, for papers by Tarek A. Abd El-Aziz Breakdown of academic impact, for papers by Yukiko Yoda Breakdown of academic impact, for papers by You Li
Rankless by CCL
2026